Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology

a systematic review and statement paper

Anna Caroli, Moritz Schneider, Iris Friedli, Alexandra Ljimani, Sophie De Seigneux, Peter Boor, Latha Gullapudi, Isma Kazmi, Iosif A Mendichovszky, Mike Notohamiprodjo, Nicholas M Selby, Harriet C Thoeny, Nicolas Grenier, Jean-Paul Vallée

Research output: Contribution to journalArticle

Abstract

Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.

Original languageEnglish
Pages (from-to)ii29-ii40
JournalNephrology Dialysis Transplantation
Volume33
Issue numbersuppl_2
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Diffusion Magnetic Resonance Imaging
Pathology
Kidney
Biomarkers
Chronic Renal Insufficiency
Fibrosis
Magnetic Resonance Imaging
International Cooperation
Water
Anisotropy
Graft Rejection
Kidney Diseases
Feasibility Studies
Acute Disease
Microcirculation
Patient Selection
Perfusion
Inflammation
Technology
Biopsy

Cite this

Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology : a systematic review and statement paper. / Caroli, Anna; Schneider, Moritz; Friedli, Iris; Ljimani, Alexandra; De Seigneux, Sophie; Boor, Peter; Gullapudi, Latha; Kazmi, Isma; Mendichovszky, Iosif A; Notohamiprodjo, Mike; Selby, Nicholas M; Thoeny, Harriet C; Grenier, Nicolas; Vallée, Jean-Paul.

In: Nephrology Dialysis Transplantation, Vol. 33, No. suppl_2, 01.09.2018, p. ii29-ii40.

Research output: Contribution to journalArticle

Caroli, A, Schneider, M, Friedli, I, Ljimani, A, De Seigneux, S, Boor, P, Gullapudi, L, Kazmi, I, Mendichovszky, IA, Notohamiprodjo, M, Selby, NM, Thoeny, HC, Grenier, N & Vallée, J-P 2018, 'Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper', Nephrology Dialysis Transplantation, vol. 33, no. suppl_2, pp. ii29-ii40. https://doi.org/10.1093/ndt/gfy163
Caroli, Anna ; Schneider, Moritz ; Friedli, Iris ; Ljimani, Alexandra ; De Seigneux, Sophie ; Boor, Peter ; Gullapudi, Latha ; Kazmi, Isma ; Mendichovszky, Iosif A ; Notohamiprodjo, Mike ; Selby, Nicholas M ; Thoeny, Harriet C ; Grenier, Nicolas ; Vallée, Jean-Paul. / Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology : a systematic review and statement paper. In: Nephrology Dialysis Transplantation. 2018 ; Vol. 33, No. suppl_2. pp. ii29-ii40.
@article{634266f489314e6dbf3984bd1bb17751,
title = "Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology: a systematic review and statement paper",
abstract = "Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.",
author = "Anna Caroli and Moritz Schneider and Iris Friedli and Alexandra Ljimani and {De Seigneux}, Sophie and Peter Boor and Latha Gullapudi and Isma Kazmi and Mendichovszky, {Iosif A} and Mike Notohamiprodjo and Selby, {Nicholas M} and Thoeny, {Harriet C} and Nicolas Grenier and Jean-Paul Vall{\'e}e",
year = "2018",
month = "9",
day = "1",
doi = "10.1093/ndt/gfy163",
language = "English",
volume = "33",
pages = "ii29--ii40",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "suppl_2",

}

TY - JOUR

T1 - Diffusion-weighted magnetic resonance imaging to assess diffuse renal pathology

T2 - a systematic review and statement paper

AU - Caroli, Anna

AU - Schneider, Moritz

AU - Friedli, Iris

AU - Ljimani, Alexandra

AU - De Seigneux, Sophie

AU - Boor, Peter

AU - Gullapudi, Latha

AU - Kazmi, Isma

AU - Mendichovszky, Iosif A

AU - Notohamiprodjo, Mike

AU - Selby, Nicholas M

AU - Thoeny, Harriet C

AU - Grenier, Nicolas

AU - Vallée, Jean-Paul

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.

AB - Diffusion-weighted magnetic resonance imaging (DWI) is a non-invasive method sensitive to local water motion in the tissue. As a tool to probe the microstructure, including the presence and potentially the degree of renal fibrosis, DWI has the potential to become an effective imaging biomarker. The aim of this review is to discuss the current status of renal DWI in diffuse renal diseases. DWI biomarkers can be classified in the following three main categories: (i) the apparent diffusion coefficient-an overall measure of water diffusion and microcirculation in the tissue; (ii) true diffusion, pseudodiffusion and flowing fraction-providing separate information on diffusion and perfusion or tubular flow; and (iii) fractional anisotropy-measuring the microstructural orientation. An overview of human studies applying renal DWI in diffuse pathologies is given, demonstrating not only the feasibility and intra-study reproducibility of DWI but also highlighting the need for standardization of methods, additional validation and qualification. The current and future role of renal DWI in clinical practice is reviewed, emphasizing its potential as a surrogate and monitoring biomarker for interstitial fibrosis in chronic kidney disease, as well as a surrogate biomarker for the inflammation in acute kidney diseases that may impact patient selection for renal biopsy in acute graft rejection. As part of the international COST (European Cooperation in Science and Technology) action PARENCHIMA (Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease), aimed at eliminating the barriers to the clinical use of functional renal magnetic resonance imaging, this article provides practical recommendations for future design of clinical studies and the use of renal DWI in clinical practice.

U2 - 10.1093/ndt/gfy163

DO - 10.1093/ndt/gfy163

M3 - Article

VL - 33

SP - ii29-ii40

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - suppl_2

ER -